Intellectual Property Law (CLE)

What’s In and What’s Out in PTAB AIA Trial Proceedings

2021-05-10T03:28:58-04:00

Recent and emerging developments continue to reshape the Patent Trial and Appeal Board’s (PTAB’s) America Invents Act (AIA) trial landscape. The Board’s increasing reliance on 35 U.S.C. § 314 discretionary denial is under attack in Google v. Uniloc and by some requests for a congressional investigation. One of the most notable cases is Facebook v. Windy City, which settles the issue of same-party or new issue joinder for inter partes reviews (IPRs).

Trends and Developments in Trade Secrets: What Companies Must Know and Do

2021-05-13T05:39:34-04:00

Fiscal year 2019 had been an eventful year for trade secrets and with the previous important developments, it is expected that 2020 will be another busy year for this area of law. Foremost, because the value of intangible assets such as trade secrets has significantly increased, the risk of trade secrets theft has also skyrocketed. This gave light to trade secret protection as a substantial legal tool for businesses to preserve confidential information to keep their competitivity.

Trade Secret Misappropriation: What You Should Know and Do

2022-12-05T22:48:44-05:00

The year 2020 has seen an upsurge in the number of disputes and investigations concerning trade secret misappropriation, and this is expected to continue in 2021. Currently, a significant number of Federal Bureau of Investigation (FBI) investigations revolve around "Chinese technology theft," which are done either by using insiders or any cyber means. Further complicating the trade secret protection landscape is the new risks posed by the recent shift of companies to remote work.

Biosimilars and the BPCIA: Exploring Trends, Developments, and Critical Issues

2021-05-06T21:15:13-04:00

As the biosimilar industry continues to grow, significant legal developments and trends also continue to emerge and pose challenges to market participants. Questions currently hounding the future of the Biologics Price Competition and Innovation Act (BPCIA) litigation and regulatory pathway include the newly introduced Biologic Patent Transparency Act, the ongoing debates on the constitutionality of the Affordable Care Act (ACA), and the potential unavailability of inter partes and post-grant review proceedings for biosimilar manufacturers.

Effective Brand Protection Strategy: A Comprehensive Guide for Companies

2022-12-29T03:32:06-05:00

The rise of e-commerce in recent years had significantly helped businesses to gain better customer engagement and, thus, improve bottom lines. However, along with the surge of business opportunities on the internet, is the influx of criminals selling fake products and standing up brand infringing sites used for stealing credentials and propagating scams.

Section 101 Patentable Subject Matter: American Axle, How We got Here, and Where Are We Going?

2021-03-22T23:58:28-04:00

Issues on Section 101 patent eligibility have been significantly important, both for patent owners and defendants in patent litigations. With notable court decisions, such as American Axle, continuously raising the bar in this area of law, it is expected that developments under 35 U.S.C. § 101 will likely continue to bring complexity and challenges to inventors, owners, litigating parties, and applicants alike.

Go to Top